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ABSTRACT
Background: High concentrations of homocysteine have been
linked to a greater risk of Alzheimer disease, dementia, and cognitive
decline.
Objective: We evaluated the association between homocysteine and
4.5-y combined incidences of dementia and cognitive impairment
without dementia (CIND) in a cohort of 1779 Mexican Americans
aged 60–101 y.
Design: Homocysteine, red blood cell (RBC) folate, and plasma
vitamin B-12 were measured at baseline. New cases of dementia or
CIND were ascertained by neuropsychological and clinical exami-
nations and expert adjudication. We used proportional hazards mod-
els to estimate the risk of homocysteine-associated dementia or
CIND and the influence of RBC folate and plasma vitamin B-12 on
that association.
Results: High homocysteine concentrations were associated with a
greater risk of dementia or CIND: hazard ratio (HR): 2.39; 95% CI:
1.11, 5.16. Plasma vitamin B-12 modified the association between
homocysteine and the outcome. The rates of dementia or CIND
associated with homocysteine for those in the lowest and highest
tertiles of vitamin B-12, respectively, were significantly higher (HR:
1.61, P  0.04) and lower (HR: 0.94, P  0.015) than the risk for
those in the middle tertile.
Conclusions: Homocysteine is an independent risk factor for both
dementia and CIND. Higher plasma vitamin B-12 may reduce the
risk of homocysteine-associated dementia or CIND. Am J Clin
Nutr 2007;85:511–7.
KEY WORDS Homocysteine, B vitamins, dementia, cogni-
tive impairment without dementia, red blood cell folate
INTRODUCTION
Biomarkers associated with the risks of late-life dementia and
Alzheimer disease (AD) are not well described or understood.
Longitudinal cohort studies linked high concentrations of homo-
cysteine with a greater risk of AD or dementia (1, 2), whereas
others did not find an association (3). Homocysteine, a sulfhydryl
amino acid, is a product of the methionine cycle that is derived
from dietary protein. The homocysteine concentration is influ-
enced by folate and vitamin B-12 and is modifiable through B
vitamin supplementation (4, 5). Homocysteine has been linked to
a greater risk of cardiovascular disease in some studies (6, 7),
although others authors have raised questions about the mecha-
nisms underlying these findings (8). A meta-analysis of 30 stud-
ies of homocysteine and stroke or ischemic heart disease sug-
gested that low homocysteine could be associated with a lower
risk of either outcome (9). No rrandomized clinical trials of folic
acid supplementation in relation to dementia or AD as outcomes
have yet been published. A small trial reported that B vitamin
supplementation lowered homocysteine in AD patients (10). De-
spite the potential benefits of B vitamin supplementation for
lowering homocysteine, a review of folic acid with or without
vitamin B-12 supplementation did not find evidence of a benefit
for cognition (11). Our group (12, 13) reported in previous cross-
sectional analyses of the current study that higher homocysteine
was associated with worse cognitive scores and that homocys-
teine was higher at baseline in participants with dementia than in
those without dementia. However, these comparisons are likely
to reflect reverse causation. After folate fortification was imple-
mented in the United States (in 1998), red blood cell (RBC) folate
concentrations reported by the National Health and Nutrition
Examination Survey (NHANES) in 1999–2002 showed less
prevalence of folate deficiency than was seen before 1998, and
plasma homocysteine declined by 15% after 1998 (14). That
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study was initiated after 1998 and may reflect postfortification
concentrations of folate.
The goal of this analysis is to evaluate the association between
baseline plasma homocysteine and the 4.5-y combined incidence
of the outcomes of dementia and cognitive impairment without
dementia (CIND). The influence of RBC folate and plasma vi-
tamin B-12 on this association was evaluated.
SUBJECTS AND METHODS
Population
The analysis presented here is based on an ongoing cohort
study (n  1779) of older (aged 60–101 y), primarily Mexican
American, Latinos who were residing in the Sacramento Valley
of California from 1997 to 1999. Details of the recruitment and
baseline assessment and the protocols for diagnosing baseline
dementia and CIND were published elsewhere (15, 16).
All subjects gave written informed consent. The study proce-
dures were approved by the institutional review boards of the
University of California, Davis, and the University of Michigan.
Diagnosis
After baseline assessment, the cognitive screening protocol
required that any participant should be referred for clinical eval-
uation who declined from the baseline score by 3 points (SE of
measurement) on the Verbal Episodic Memory test or by 8
points on the Modified Mini Mental State Exam (17) or whose
current Verbal Episodic Memory or Modified Mini Mental State
Exam test score was below the 20th percentile. These partici-
pants underwent an expanded neuropsychological test battery
and a clinical examination by a geriatrician. Case adjudication
was done by an expert panel that included a neurologist, a geri-
atrician, and a neuropsychologist. Dementia and CIND cases
were referred for magnetic resonance imaging for use in assign-
ing diagnoses. Cases were classified as having dementia if they
failed one or more cognitive tests on the battery (including one
memory test) at the 10th percentile; were limited in daily inde-
pendent function as measured by the Informant Questionnaire on
Cognitive Decline in the Elderly, a standard interview done with
informants (18); and were judged by the expert panel to meet the
dementia criteria of the Diagnostic and Statistical Manual of
Mental Disorders 3rd edition, the National Institute of Neuro-
logical and Communicative Disease and Stroke, or the Alzhei-
mer’s Disease and Related Disorders Association. Cases were
diagnosed as having CIND if they failed (10th percentile) one
additional cognitive test battery after screening but did not meet
the criteria for dementia, usually because they were impaired in
only one cognitive domain or had a nonmemory multidomain
impairment that was judged to be clinically questionable or in-
significant. Ten dementia cases that were not previously diag-
nosed by the study were identified from a mortality search that
obtained multiple causes from death certificates. Those cases
were assigned a diagnosis of dementia after case review by the
same panel, and the year of death was given as the year of
diagnosis.
Biomarkers
At baseline, fasting blood was collected from each participant
by standard venipuncture into evacuated tubes with and without
EDTA. The blood was transported on ice to the Medical Center
Clinical Laboratory at the University of California, Davis, for
processing within 4 h of collection, and it was isolated and stored
at 80 °C until it was analyzed. Plasma homocysteine concen-
trations were measured by HPLC with postcolumn fluorescence
detection (19). RBC folate was measured by using automated
chemiluminescence assay [ACS 180; Chiron Diagnostics (now
Bayer Diagnostics), Tarrytown, NY]. Plasma vitamin B-12 con-
centrations were measured by using a radioassay (Quantaphase
II; BioRad Diagnostics, Hercules, CA). Serum creatinine was
analyzed by using a standard spectrophotometric assay. Glomer-
ular filtration rate (GFR) was calculated by using the formulas
GFR  (186  serum creatinine  age) for males and GFR 
(186  serum creatinine  age) females (20)
Other covariates
Age and education were measured in years. Birthplace was
measured by self- report of country of birth (United States, Mex-
ico, or another Latin American country). Self-reported physician
diagnoses of renal disease or liver disease were obtained by
medical history interview.
Vitamin use was assessed through an inventory done at the
home visit. The coding system used was the Centers for Disease
Control and Prevention National Center for Health Statistics
Ambulatory Care Drug Database System. This procedure coded
all nutritional supplements into Group 0913—Vitamins/Miner-
als. From this coding, the list of ingredients was reviewed to
classify the supplement for the presence of B vitamins. Vitamins
were coded as multivitamin with vitamin B, only B vitamins, or
other vitamins.
Statistical analysis
Analyses were restricted to participants who were free of de-
mentia or CIND at baseline and who had available data on the
biomarkers of interest. Biological samples were not obtained for
the entire sample because of refusals or technical problems with
the sample. After all these exclusions, 1405 participants were
available for these analyses.
We evaluated the association between homocysteine concen-
trations and the combined incidences of dementia and CIND.
Statistical power was thought to be too low to permit examination
of associations with dementia alone or with a specific diagnosis
of dementia. Combined incidence rates of dementia and CIND
were calculated by using the cumulative incidence technique, in
which the total number of new cases was the numerator and the
cumulative number of person-years was the denominator. Time
from enrollment in the study until diagnosis, death, or the most
recent contact date was used for estimating person-years. For
subjects lost to follow-up or who refused follow-up and were not
known to be dead, the last date of contact was used in calculations
of follow-up time or age at diagnosis. For those alive, free of
dementia or CIND, and still active in the study, the most recent
visit date was used. For those who died, the date of death was
used. Rate ratios within sex by age and between the sexes were
calculated. We examined the untransformed mean differences
for each of the 4 biomarkers by birthplace, sex, age, baseline
stroke, cognitive status, and vitamin use by using a general
linear model. The association between education and the 4
untransformed biomarkers was tested by using Spearman’s
rank correlation.
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Plasma homocysteine, RBC folate, and GFR values were log
transformed for regression analyses. For analyses predicting in-
cident dementia or CIND, we used a series of proportional haz-
ards models in which the time variable was the time from age at
baseline to age at diagnosis. Covariates were included in the
model if they were associated with homocysteine concentrations
and if inclusion influenced the association between homocys-
teine concentrations and the outcome of dementia or CIND by at
least 10%. The fit of the models was tested by using Akaike’s
Information Criterion (21), a goodness-of-fit test for selecting
models. When the square root of plasma vitamin B-12 was in-
cluded in the models, the Akaike’s Information Criterion fit test
improved significantly, and therefore this transformation was
retained in the analysis. Model 1 was unadjusted and included all
covariates separately. Because RBC folate and GFR were not
associated with the outcome in the bivariate model, model 2
included only homocysteine and the square root term for plasma
vitamin B-12. Only the inclusion of plasma vitamin B-12 influ-
enced the association of homocysteine and outcome. Model 3
included homocysteine, vitamin B-12, baseline stroke, and edu-
cation. Model 4 excluded participants who had baseline stroke
and included all other covariates from model 3. RBC folate, renal
function, birthplace, sex, and several vitamin measures were not
associated with the outcome and did not influence the association
of homocysteine with the outcome; therefore, they were dropped
after model 1.
We compared 2 models for vitamin B-12, each with a linear
term; one model added a squared term for vitamin B-12 and the
other added a square root term for vitamin B-12. The square root
of plasma vitamin B-12 was associated with a greater risk of
dementia or CIND, and the model fit was better than that for the
model with the squared term. To further test this nonlinear asso-
ciation, we used indicator variables representing the highest and
lowest tertiles of vitamin B-12 and entered these into a Cox
regression model in which the middle tertile was the reference
term. To test for interactions between vitamin B-12 and homo-
cysteine, we added to models multiplicative interaction terms
including these indicator variables and homocysteine (homocys-
teine  vitamin B-12 tertile 1; homocysteine  vitamin B-12
tertile 3). The inclusion of covariates followed the same proce-
dure as for the models without interaction terms.
RESULTS
We identified 62 new dementia cases and 55 new CIND cases.
Of these 2 groups of cases, 93 had homocysteine values. Forty-
four percent (n  27) of the dementia cases were classified as
AD, 10 as vascular dementia, and 9 as mixed AD and vascular
dementia. The remainder were either other dementias (n  1) or
undetermined (n  15). All diagnoses were combined in these
analyses.
Comparison of the new CIND cases with the new dementia
cases for baseline cognitive status showed the following: the
mean word list scores were 7.05 and 6.15 (P  0.14), and the
mean Modified Mini Mental State Exam scores were 81.3 and
75.3 (P  0.091) for CIND and dementia, respectively. New
CIND cases did not differ significantly from new dementia cases
in mean age (CIND: 74 y; dementia: 76 y; P  0.11).
The cumulative 4.5-y incidence rates per 1000 person-years
for the combined outcomes by baseline age group and by sex are
shown in Table 1. Sex- and age-specific rates along with crude
combined incidence rates for dementia and CIND are shown. The
crude rate ratio for sex (M/F) was 0.85. In the men, rate ratios
(RRs) by age group were 70–79 y versus 70 y: RR: 1.43 and
80 y versus 70 y: RR: 2.31. In the women, the RRs by age
group were 70–79 y versus 70 y: RR:1.26 and 80 y versus
70 y: RR:2.35. In analysis with a proportional hazards model,
no association was found between sex and the combined inci-
dence of dementia and CIND [hazard ratio (HR): 1.19, 95% CI:
0.78, 1.81]. In addition, no significant interaction was found
between sex and age.
Homocysteine was elevated (	13 umol/L) in 16.5% (252/
1529) of the sample. RBC folate (160 ng/mL) was low in
0.64% (9/1403), vitamin B-12 was low (200 pg/mL) in 6.4%
(92/1440), and GFR was low (60 mL · min1 · 1.73 m2) in
61.5% (939/1528). The means  SDs for homocysteine, plasma
vitamin B-12, RBC folate, and GFR overall by birthplace, sex,
age at baseline, incident dementia or CIND, baseline stroke, and
vitamin use are shown in Table 2. Homocysteine was signifi-
cantly lower in women than in men, higher in those at older ages,
and higher in those with a baseline stroke; it did not differ for
other covariates. Plasma vitamin B-12 was significantly higher
in men and lower in those at older ages; it did not differ by
dementia or CIND status, baseline stroke, or vitamin use. Further
analysis suggested that vitamin B-12 was higher in those with
renal disease (447 and 486 pg/mL, respectively; P  0.034) after
adjustment for age and sex or in those with liver disease (449.4
and 507.2 pg/mL, respectively; P  0.04) than in those without
those conditions. RBC folate was significantly lower in
Mexican-born participants than in those born elsewhere and did
not differ by age, sex, baseline stroke, use of vitamins, or de-
mentia or CIND status. GFR did not differ significantly for any
covariates. Education was significantly associated (Spearman’s
TABLE 1












n no. n no.
70 y 358 1268.31 7.88 (10)2 469 1735.98 9.79 (17)
70–79 y 222 1420.81 11.26 (16) 348 2275.69 12.30 (28)
	80 y 48 493.61 18.23 (9) 76 650.83 23.05 (15)
Total 628 3182.74 11.00 (35) 893 4662.50 12.87 (60)
1 No significant association was found between sex and incidence, and no interaction was found between sex and age.
2 The number of cases per 1000 person-years in parentheses (all such values).
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correlation) with all 4 biomarkers as follows: homocysteine,
0.095; P  0.0001; vitamin B-12, 0.093; P  0.0003; RBC
folate, 0.12; P 0.0001; and GFR, 0.085; P  0.0006. The
results from a series of proportional hazards models that test the
association between homocysteine and the incidence of demen-
tia or CIND are shown in Table 3.
Homocysteine
In model 1 (unadjusted), homocysteine was significantly as-
sociated with a greater risk of dementia or CIND. After the
addition of a square-root term for plasma vitamin B-12 (model 2),
the HR was 55% greater than that in the unadjusted model. The
addition of stroke and education (model 3) reduced the HR for
homocysteine by 32% compared with model 2, and the confi-
dence limit included 1.0. The association between homocysteine
and dementia or CIND was significant in model 4 (excluding
baseline stroke), and the HR increased by 29% compared with
model 3.
A continuous term for plasma vitamin B-12 (square root) was
significantly associated with a greater risk of dementia or CIND
in all models. This indicated a U-shaped, nonlinear association
between plasma vitamin B-12 and the incidence variable. To
further test differences between the comparisons of the low and
high tertiles with the middle tertile, a separate proportional haz-
ards model was developed including 2 indicator variables for the
lowest (340 pg/mL) and highest (	498 pg/mL) tertiles of
plasma vitamin B-12 to be used in comparison with the middle
tertile (	340  498 pg/mL) as a reference category. The risk of
dementia or CIND was significantly higher in the highest than in
the middle vitamin B-12 tertile (HR: 2.5; 95% CI: 1.31, 4.54).
The risk of dementia or CIND was higher in the lowest than in the
middle vitamin B-12 tertile, but the confidence limit included 1.0
(HR: 1.63; 95% CI: 0.88, 3.01). Adjustments for RBC folate,
homocysteine, GFR, education, and birthplace did not influence
these associations.
Interactions between vitamin B-12 and homocysteine were
tested in a model including vitamin B-12 tertiles, homocysteine,
2 indicator variables (lowest and highest tertiles of vitamin
B-12), and 2 interaction terms between the vitamin B-12 indica-
tor variables and homocysteine. In those in the lowest tertile of
vitamin B-12, compared with those in the middle tertile, homo-
cysteine was associated with a significantly greater risk of de-
mentia or CIND (HR: 1.61; P for interaction  0.04). In those in
the highest vitamin B-12 tertile, compared with those in the
middle tertile, homocysteine was associated with a slightly lower
risk of dementia or CIND (HR: 0.94; P  0.015). Adjustment for
education, baseline stroke, RBC folate, or renal function did not
influence this association; nor did exclusion of baseline stroke.
The risk of dementia or CIND associated with homocysteine by
low and high vitamin B-12 tertiles compared with the middle
tertile for 2 models is illustrated in Figure 1. The bivariate model
is unadjusted, and model 1 is adjusted for education.
TABLE 2









mol/L pg/mL ng/mL mL · min1 · 1.73 m2
Overall descriptive statistics 10.78  6.46 (4.0–129.2)3 452.59  203.49 (22.0–1000) 504.69  159.89 (50.0–900.0) 60.48  52.98 (14.56–1123.26)
Covariates
Birthplace
United States (n  776) 10.74  0.234 431.26  7.55 523.55  5.995 61.99  2.00
Mexico or Latin America (n  753) 10.83  0.24 475.02  7.73 485.56  5.99 58.89  2.03
Sex
Female (n  894) 10.07  4.135 478.52  252.635 510.29  158.08 45.55  33.585
Male (n  635) 11.80  8.76 417.15  190.56 497.05  162.23 81.62  71.94
Baseline age (y)6
60–69 (n  790) 10.26  0.235 461.40  7.6 502.76  5.95 58.95  1.99
70–79 (n  597) 10.91  0.26 449.46  8.65 511.88  6.81 61.78  2.28
	80 (n  147) 13.24  0.54 415.96  17.92 483.85  13.96 63.37  4.68
Dementia or CIND
Yes (n  93) 11.68  4.06 479.53  252.74 481.05  147.60 56.52  22.41
No (n  1436) 10.73  6.65 450.85  202.04 506.22  9160.62 60.75  57.35
Baseline stroke
Yes (n  121) 12.05  4.797 451.71  234.89 513.32  155.90 65.37  36.09
No (n  1408) 10.68  6.64 452.66  202.84 504.02  160.26 60.06  57.21
Multivitamins with vitamin B
Yes (n  374) 10.74  6.24 451.76  206.63 497.82  159.94 59.64  61.55
No (n  1153) 10.91  7.34 452.86  205.17 506.86  159.93 60.76  53.88
B vitamin alone
Yes (n  73) 10.69  4.59 468.08  214.91 495.29  156.59 58.02  28.22
No (n  1454) 16.79  6.61 451.79  205.02 505.17  160.14 60.61  56.85
Other vitamins
Yes (n  412) 10.71  6.49 447.48  214.26 507.72  154.45 62.15  71.41
No (n  1115) 10.81  6.54 454.47  202.20 503.55  161.99 59.87  48.93
1 CIND, cognitive impairment without dementia. Available biomarker data were from a general linear model.
2 n after exclusions (all such).
3 x  SD; range in parentheses (all such values).
4 x  SD (all such values).
5 P  0.0001.
6 Bonferroni correction applied.
7 P  0.03.
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Red blood cell folate and glomerular filtration rate
RBC folate and GFR were not associated with the outcome in
any of the models tested. Those values were not retained in
models 2–4.
Baseline stroke, demographic factors, and vitamin use
Stroke at baseline was associated with a greater risk of demen-
tia or CIND. Education was significantly associated with a lower
risk of dementia or CIND and was included in models 2–4. Sex,
birthplace, and vitamin use were not associated with the outcome
in the unadjusted model and were not included in models 2–4.
DISCUSSION
We found that homocysteine is associated with a greater risk
of dementia or CIND that is independent of RBC folate. The
influence of homocysteine on dementia or CIND may be modi-
fied by plasma vitamin B-12. The current study has improved on
TABLE 3
Hazard ratios (95% CIs) for combined 4.5-y incidence of dementia or cognitive impairment without dementia for each covariate with age at diagnosis or










Homocysteine2 1.58 (1.88, 2.83) 2.45 (1.26, 4.75) 1.85 (0.93, 3.70) 2.39 (1.11, 5.16)
Plasma vitamin B-123 1.04 (1.01, 1.08) 1.06 (1.02, 1.10) 1.05 (1.10, 1.09) 1.07 (1.02, 1.11)
RBC folate2 0.85 (0.57, 1.24) —4 — —
Glomerular filtration rate2 0.93 (0.57, 1.50) — — —
Baseline stroke (0, 1)5 2.93 (1.76, 4.86) — 2.53 (1.43, 4.45) —
Education (y) 0.94 (0.90, 0.98) — 0.94 (0.90, 0.99) 0.95 (0.91, 1.00)
Sex (female versus male) 1.14 (0.76, 1.70) — — —
Birthplace (Mexico versus USA) 0.93 (0.62, 1.40) — — —
Multivitamins with vitamin B (0, 1)5 0.94 (0.64, 1.48) — — —
Only B vitamins (0, 1)5 0.30 (0.07, 1.26) — — —
Other vitamins (0, 1)5 1.19 (0.78, 1.81) — — —
1 RBC, red blood cell. Except for homocysteine, covariates were retained in the model only if they were associated with the outcome and influenced the
hazard ratio. Bivariate model, unadjusted coefficients from separate models; model 2, simultaneous adjustment for all biomarkers; model 3, model 2 
 age,
education, baseline stroke, and sex; model 4, model 3 excluding baseline stroke. The total sample available for analysis after exclusions and missing data on
biomarkers was n  1519, 1332, 1332, and 1235 for bivariate model and models 2, 3, and 4, respectively.
2 Square root.
3 Natural log.
4 The covariate was not included in the model (all such).
5 0  absent, 1  present.
FIGURE 1. Association between homocysteine and dementia or cognitive impairment without dementia (CIND) by low (■ ; 340 pg/mL) and high (z;
	498 pg/mL) vitamin B-12 tertiles compared with the vitamin B-12 middle tertile from 2 proportional hazards models—model 1 including only vitamin B-12
and model 2 adding adjustment for education. P values are for the interaction terms between vitamin B-12 indicator variables and homocysteine.
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our earlier cross-sectional research by providing evidence of an
association between baseline homocysteine and the combined
incidence of dementia and CIND in those who were free of
disease at baseline. Our findings are consistent with some other
work on this topic. For example, Seshadri et al (1) reported that
the risk of AD was nearly doubled in association with high
concentrations of homocysteine. In contrast, Kado et al (22)
reported no association between folate and cognitive decline,
Luchsinger et al (3) found no association between homocysteine
and cognitive decline or AD, and Ravaglia et al (2) reported a
2-fold increase in the risk of dementia associated with hyperho-
mocystenemia (	15 mol/L) in older Italians. Ellensin et al (23),
who summarized studies examining homocysteine and demen-
tia, concluded that the evidence was insufficient to support a
randomized trial of folic acid supplementation, but this assess-
ment was based mainly on cross-sectional studies of cognitive
status. Stott et al (5) reported that randomized supplementation
with vitamin B-12 and folate reduced homocysteine in those at
high risk of cardiovascular disease recurrence, but this treatment
had no effect on cognitive function.
Several lines of evidence may help to explain the link between
homocysteine and the risk of dementia or CIND. The association
between vascular disease and homocysteine is an obvious pos-
sibility; 2 analyses provided some evidence of greater volumes of
white matter associated with elevated homocysteine (24–26).
However, Durga et al (8) and Brattstrom and Wilcken (27), in
careful critical reviews, found conflicting reports of the evidence
supporting an association between white matter and homocys-
teine. Higher homocysteine has been associated with atrophy of
the medial temporal lobe in a small study comparing AD cases
with controls (26). In excluding baseline stroke (model 3), we
attempted to reduce confounding by vascular disease of the
homocysteine-dementia association. Stroke has been associated
with homocysteine (28) and is also a strong predictor of dementia
in the current study. The fact that an association remains after the
exclusion of stroke suggests that pathways may not be restricted
to vascular factors.
We did not find an association between RBC folate and de-
mentia or CIND. Ravaglia et al (2) found a greater risk of de-
mentia to be associated with low folate. RBC folate values from
population-based studies of Mexican Americans aged 	65 y
have not been published. Ganji and Kafai (14) reported, for all
age groups in NHANES, a 56% increase in mean RBC folate
concentrations (from 361 to 564 ng/mL) between 1988–1994
and 1999–2000 and a 2.3% increase between 1999–2000 and
2001–2002 (from 564 to 577 ng/mL). Other evidence from
NHANES suggests that RBC folate changes with age, the sub-
jects in the current study have an average age of 75 y at the time
of this writing. Our ability to observe an association between
RBC folate and dementia or CIND may be influenced by the lack
of low folate values. Because we adjusted for folate and found no
effects, it is unlikely that the results are due to underlying defi-
ciency. The U-shaped association between plasma vitamin B-12
and dementia or CIND is not surprising, because vitamin B-12
deficiency is an established risk factor for dementia, and exces-
sive vitamin B-12 is a marker for renal and liver disease. The
modification by vitamin B-12 of the association between homo-
cysteine and dementia or CIND suggests that higher concentra-
tions of vitamin B-12 can reduce the risk of dementia or cognitive
impairment associated with homocysteine.
CIND is an entity conceptually similar to mild cognitive im-
pairment (MCI), a condition felt to be intermediate between
normal cognition and dementia (29). Our definition of CIND is
not precisely the definition that is currently being applied for
classifying MCI, but it is similar. Few population-based studies
exist of MCI and the rates of conversion from MCI to dementia,
and none exist in Mexican Americans. Larrieu et al (30) reported
that conversion from MCI at baseline to dementia was 3.5% and
that nearly 19% of new MCI cases found at baseline converted to
dementia during follow-up. Amieva et al (31) reported a 32%
conversion rate. The conversion rate in the current study was
lower than the rates in those reports, but CIND was a predictor of
earlier mortality and attrition in the current study, so that some
cases that may have progressed to dementia had, instead, died.
Moreover, the studies of Larrieu et al and Amieva et al are not
comparable with the current study, because they are based on
European samples of comparatively well-educated participants.
Most other published work on this topic has relied on samples of
patients or other nonrandom sources of participants and are not
comparable.
The current study has some limitations, in that it does not yet
include sufficient numbers of AD cases to allow separate exam-
ination of diagnoses. As is the case for all cohort studies of elderly
populations, attrition from the current study because of death and
loss to follow-up may attenuate our estimates by selecting out
more vulnerable participants and those who are more likely to
develop cognitive impairment. Exclusion of baseline stroke
cases may help account for the effects of subclinical disease
on homocysteine at baseline. However, we do not have direct
measures of underlying vascular or AD pathology in the entire
sample.
No direct way exists to evaluate the effect of folic acid forti-
fication on these results, because the study started after fortifi-
cation was implemented and we have no historical dietary data.
Furthermore, no population-based studies of older Mexican
Americans have been published that reflect changes in popula-
tion folate concentrations before and after fortification that
would be appropriate for comparison. The low prevalence of
folate deficiency in the current analysis suggests that the contri-
bution of folate deficiency to the population risk of dementia may
be lower than expected and that the contribution of homocysteine
to dementia risk may derive from sources other than folate. Three
recent, well-powered, randomized clinical trials, designed to test
the effects of B vitamins on homocysteine, cognitive outcomes
and cardiovascular events, respectively, did not find any effects
on the specified outcomes, although the supplements did lower
homocysteine (32–34). The findings of the current study and of
these recent trials have implications for potential B vitamin sup-
plementation as a treatment for dementia. It may be that B vita-
min supplementation influences homocysteine but does not
strongly influence the risk of cognition or of vascular diseases
that are potential pathways for the link between homocysteine
and dementia. Homocysteine may be an early marker of a sub-
clinical pathologic condition leading to dementia, or it may be
that the pathway by which homocysteine influences cognitive
performance is not influenced by folate. Most studies have not
hadsufficient follow-up time toseparate subclinicalpathologiccon-
ditins from cause or diagnosis. However, findings from the Fra-
mingham Study (1, 34) and the current study, both of which have
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longer follow-up times, suggest that homocysteine may be an inde-
pendent predictor of dementia outcomes. The role of vitamin B-12
in dementia risk should be further evaluated.
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